Dublin 6

• STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Pending
  2025-522145-21-00 5 Metastatic hormone sensitive prostate cancer
• CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk orophar … Ended recruitment
  2024-516108-41-00 5 2024-12-09 Oropharyngeal cancer
• Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and surv … Ended recruitment
  2024-511306-23-00 5 2024-07-01 Breast cancer, colon cancer, rectal cancer, stomach cancer, oesophagea
• DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 dou … Ended recruitment
  2024-514565-18-00 5 2021-07-20 Localised Very High-Risk Cancer of the Prostate
• A clinical research study comparing two cisplatin dosing schedules combined with radiation for patients with advanced head and neck cancer. Halted
  2024-515237-15-00 10 2025-01-21 Advanced head and neck cancer
• Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended
  2022-502339-20-00 4 2023-11-15 Squamous cell carcinoma of head and neck
• Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat … Ended
  2024-514808-13-00 5 2015-03-06 Localised prostate cancer at high risk of recurrence

Showing 1–7 of 7 trials